<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="editorial" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">abchf</journal-id>
<journal-id journal-id-type="publisher-id">abchf</journal-id>
<journal-title-group>
<journal-title>ABC Heart Fail Cardiomyop</journal-title>
<abbrev-journal-title abbrev-type="publisher">ABC Heart Fail Cardiomyop</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2764-3107</issn>
<publisher>
<publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.36660/abchf.20230090</article-id>
<article-id pub-id-type="publisher-id">abchf.20230090</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Viewpoint</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Resistance to Loop Diuretics: How to Address it in the Current Scenario?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-9049-1805</contrib-id>
<name><surname>Savaris</surname><given-names>Simone L.</given-names></name>
<role>Writing of the manuscript and Critical revision of the manuscript for content</role>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-2612-8040</contrib-id>
<name><surname>Andrade</surname><given-names>Fernanda Almeida</given-names></name>
<role>Writing of the manuscript and Critical revision of the manuscript for content</role>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-0706-0933</contrib-id>
<name><surname>Schwartzmann</surname><given-names>Pedro V.</given-names></name>
<role>Writing of the manuscript and Critical revision of the manuscript for content</role>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c1"/>
</contrib>
<aff id="aff1">
<label>1</label>
<institution content-type="orgname">Hospital São Luiz</institution>
<institution content-type="orgdiv1">Rede D’Or</institution>
<addr-line>
<named-content content-type="city">São Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Hospital São Luiz, Rede D’Or, São Paulo, SP – Brazil</institution>
</aff>
<aff id="aff2">
<label>2</label>
<institution content-type="orgname">Universidade Federal de São Paulo</institution>
<addr-line>
<named-content content-type="city">São Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Universidade Federal de São Paulo / UNIFESP, São Paulo, SP – Brazil</institution>
</aff>
<aff id="aff3">
<label>3</label>
<institution content-type="orgname">Ribeirão Preto-SP e Centro Avançado de Pesquisa</institution>
<institution content-type="orgdiv1">Hospital da Unimed</institution>
<addr-line>
<named-content content-type="city">Ribeirão Preto</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Hospital da Unimed, Ribeirão Preto-SP e Centro Avançado de Pesquisa – CAPED, Ribeirão Preto, SP – Brazil</institution>
</aff>
</contrib-group>
<author-notes>
<corresp id="c1"><bold>Mailing Address: Pedro V. Schwartzmann •</bold> Centro de Pesquisa - CAPED - Av. Cel. Fernando Ferreira Leite, 1540. Postal Code <postal-code>14026-900</postal-code>, Centro Médico Ribeirão Shopping, Jardim California, Ribeirão Preto, SP - Brazil E-mail: <email>pedrovs.usp@gmail.com</email></corresp>
<fn fn-type="conflict"><p><bold>Potential conflict of interest</bold></p>
<p>No potential conflict of interest relevant to this article was reported.</p></fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub">
<day>31</day>
<month>12</month>
<year>2023</year></pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2023</year></pub-date>
<volume>3</volume>
<issue>2</issue>
<elocation-id>e20230090</elocation-id>
<history>
<date date-type="received"><day>23</day><month>11</month><year>2023</year></date>
<date date-type="rev-recd"><day>16</day><month>12</month><year>2023</year></date>
<date date-type="accepted"><day>16</day><month>12</month><year>2023</year></date>
</history>
<permissions>
<license license-type="open-access" xml:lang="en" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
</license>
</permissions>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Diuretics</kwd>
<kwd>Resistance</kwd>
<kwd>Refractoriness</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="16"/>
</counts>
</article-meta>
</front>
<body>
<p>Persistent congestion despite the use of loop diuretics (LD) is one of the most important challenges in the management of acute heart failure (HF) and is associated with a worse prognosis. One of the main reasons for this persistence in congestion is resistance to LD, which can be defined as a reduction in sensitivity to diuretics, with reduced natriuresis and diuresis and limitation of reaching euvolemia – LD can reach up to 1/3 of patients admitted for acute HF and independently increases the risk of death by 1.37 times.<sup><xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref></sup></p>
<p>Regarding the mechanisms of LD, there are several factors possibly involved, such as bioavailability of the diuretic and delivery to its site of action, neurohormonal activation, compensatory tubular adaptation, and interaction with other drugs (<xref ref-type="table" rid="t1">Table 1</xref>). It is worth mentioning that, in patients with systemic congestion Importantly, it is possible that the occurrence of edema of intestinal loops, impairing the absorption of diuretics, may be one of the factors associated with less action of oral furosemide.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Furthermore, the presence of chronic kidney disease associated with HF leads to a lower glomerular filtration rate and, consequently, less effect of diuretics on the nephron. Hypoalbuminemia is also associated with greater resistance to LD, given the greater affinity of diuretics to albumin-bound molecules and a lesser effect of the diuretic on its site of action, which is the nephron.<sup><xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref></sup></p>
<table-wrap id="t1">
<label>Table 1</label>
<caption><title>Mechanisms of resistance to loop diuretics<sup><xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref></sup></title></caption>
<table frame="hsides" rules="groups">
<colgroup width="50%">
<col/>
<col/>
</colgroup>
<tbody style="border-bottom: thin solid; border-color: #000000">
<tr style="background-color:#E8CCBF">
<td align="center" valign="middle">Bioavailability of the diuretic and less effect on the nephron</td>
<td align="center" valign="middle">Poor adherence to diuretics <break/>Very low doses <break/>Malabsorption (e.g. edema of intestinal loops) <break/>Hypoalbuminemia <break/>Nephrotic syndrome <break/>Hepatical cirrhosis <break/>Renal malperfusion</td>
</tr>
<tr>
<td align="center" valign="top">Neurohormonal activation</td>
<td align="center" valign="top">Activation of the RAAS <break/>Sympathetic nervous system activation</td>
</tr>
<tr style="background-color:#E8CCBF">
<td align="center" valign="top">Compensatory tubular adaptation</td>
<td align="center" valign="top">Compensatory sodium retention after the effect of the diuretic <break/>Hypertrophy and hyperplasia of distal tubule cells <break/>Increased sodium absorption in the proximal and distal tubule</td>
</tr>
<tr>
<td align="center" valign="top">Interaction with other drugs</td>
<td align="center" valign="top">Ex: NSAIDs</td>
</tr>
<tr style="background-color:#E8CCBF">
<td align="center" valign="top">Incorrect diagnosis</td>
<td align="center" valign="top">lymphatic edema <break/>Intravascular volume depletion and third space edema</td>
</tr>
<tr>
<td align="center" valign="top">Poor adherence to sodium and water restriction recommendations</td>
<td align="center" valign="top" />
</tr>
<tr style="background-color:#E8CCBF">
<td align="center" valign="top">Chronic Renal Failure</td>
<td align="center" valign="top" />
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1"><p>RAAS: renin-angiotensin-aldosterone system; NSAIDs: non-steroidal anti-inflammatory drugs.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Resistance to diuretics may also occur due to greater absorption of sodium and chlorine in the proximal tubule, interfering with the sodium-potassium-chlorine cotransporter system in the distal nephron and minimizing the effect of the loop diuretic. Compensatory tubular readaptation is another mechanism that explains the lower response to the diuretic and occurs when there is an increase in sodium reabsorption in the proximal tubule. At the same time, chronic use of LD - which inhibit sodium uptake in the loop of Henle - leads to an increase in the amount of sodium in the distal tubule with compensatory hyperplasia and hypertrophy.<sup><xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref></sup></p>
<p>Neurohormonal activation is directly linked to the renin-angiotensin-aldosterone system and LD can activate this system through a variety of mechanisms, leading to greater sodium reabsorption and sodium retention after diuretic use, as well as the drop in urinary volume after several doses of diuretic. Finally, interactions with other medications can also impair the effect of LD, such as the use of non-steroidal anti-inflammatory drugs.<sup><xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref></sup></p>
<p>To overcome diuretic resistance, it is essential to understand the resistance mechanisms and look for the cause, which can be different depending on the particularities of each patient. Increasing the dose of the diuretic, opting for continuous infusion, performing sequential nephron blockade or even using hypertonic saline solution (HSS) are some options to manage cases in which resistance to LD is identified.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
<p>In the CLOROTIC and ADVOR studies, the association of diuretics from other classes together with LD in patients with acute HF was associated with a better diuretic response.<sup><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup></p>
<p>The CLOROTIC study included patients with decompensated HF and persistent congestion, and the association of oral hydrochlorothiazide with intravenous furosemide resulted in greater weight loss, greater urinary output, and decongestion, but there was worsening of renal function more frequently in patients who received thiazide diuretics, with no difference in mortality or risk of hyponatremia or hypokalemia.<sup><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup></p>
<p>The ADVOR study evaluated whether the combination of acetazolamide, a carbonic anhydrase inhibitor that reduces sodium absorption in the proximal tubule, could improve the response to LD and lead to greater and faster decongestion in patients with acute HF and volume overload. In this study, the use of a loop diuretic with a carbonic anhydrase inhibitor resulted in greater urine output and natriuresis, findings consistent with greater diuretic efficacy, with no significant difference in worsening renal function, hypokalemia or hypotension.<sup><xref ref-type="bibr" rid="B13">13</xref></sup></p>
<p>Furthermore, quantifying urinary sodium can also contribute to evaluating the response to diuretics, as demonstrated in the ADVOR study and the PUSH-AHF study. In this, the investigators evaluated the effectiveness of diuretic therapy guided by natriuresis and the early and repeated quantification of urinary sodium associated with subsequent adjustments of diuretic treatment led to a better diuretic response in the first 48 hours of treatment, with no impact on mortality or re-hospitalization.<sup><xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref></sup></p>
<p>Another alternative is the use of HSS associated with high-dose intravenous furosemide. Despite little evidence for its use, the rationale for its use is the osmotic effect, mobilizing extravascular fluid and correcting hyponatremia and hypochloremia which, as described in the resistance mechanisms previously, may be linked to diuretic resistance.<sup><xref ref-type="bibr" rid="B14">14</xref></sup></p>
<p>Furthermore, SGLT2 inhibitors, despite not being a class of diuretics per se, among other mechanisms of action, inhibit the reabsorption of glucose in the proximal convoluted tubule, resulting in glycosuria. As shown in the DICTATE-AHF study, this class of medications may also contribute to diuretic efficacy by increasing natriuresis and diuresis for the same dose of loop diuretic, reducing the total dose and duration of loop diuretic use, as well as the length of hospitalization in acutely decompensated HF patients.<sup><xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref></sup></p>
<p>In cases of refractory congestion, management can be used with a continuous infusion of furosemide at a dose of 40 to 150 mg/hour associated with sequential nephron blockade with a combination of spironolactone and hydrochlorothiazide. In cases of anasarca or refractory ascites and severe hyponatremia, paracentesis must be performed to reduce intra-abdominal pressure; Hypertonic sodium chloride solution is also suggested to increase the plasma filling rate by mobilizing fluid from the extracellular to the intracellular environment. When renal replacement therapy is indicated, ultrafiltration is associated with it; However, it is worth highlighting that the use of ultrafiltration has not been shown to be superior to diuretics in decongesting and progressing decompensated patients, in addition to having a greater potential for complications.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup></p>
<p>A suggested flowchart covering this new recent evidence is found in <xref ref-type="fig" rid="f1">figure 1</xref>.</p>
<fig id="f1">
<label>Figure 1</label>
<caption><title>Diuretic therapy management in acute heart failure.</title></caption>
<graphic xlink:href="2764-3107-abchf-003-02-e20230090-gf01.tif"/>
</fig>
<sec sec-type="conclusions">
<title>Conclusion</title>
<p>Resistance to diuretics is a frequent reality in many patients with HF and is associated with a worse prognosis. Several recent studies have addressed this problem by seeking alternative treatments for LD, either with more frequent monitoring or using natriuresis to help when combining diuretics. It is always important to seek the treatment of congestion with adequate doses of LD, association with SGLT2 inhibitors and, in refractory cases, consider the association of other classes of diuretics such as acetazolamide or thiazides.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1"><p><bold>Sources of funding</bold></p>
<p>There were no external funding sources for this study.</p></fn>
<fn fn-type="other" id="fn2"><p><bold>Study association</bold></p>
<p>This study is not associated with any thesis or dissertation work.</p></fn>
<fn fn-type="other" id="fn3"><p><bold>Ethics approval and consent to participate</bold></p>
<p>This article does not contain any studies with human participants or animals performed by any of the authors.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mullens</surname><given-names>W</given-names></name>
<name><surname>Damman</surname><given-names>K</given-names></name>
<name><surname>Harjola</surname><given-names>VP</given-names></name>
<name><surname>Mebazaa</surname><given-names>A</given-names></name>
<name><surname>Brunner-La Rocca</surname><given-names>HP</given-names></name>
<name><surname>Martens</surname><given-names>P</given-names></name>
<etal/>
</person-group>
<article-title>The Use of Diuretics in Heart Failure with Congestion - A Position Statement from the Heart Failure Association of the European Society of Cardiology</article-title>
<source>Eur J Heart Fail</source>
<year>2019</year>
<volume>21</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1002/ejhf.1369</pub-id>
</element-citation>
<mixed-citation>Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The Use of Diuretics in Heart Failure with Congestion - A Position Statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137-55. doi: 10.1002/ejhf.1369.</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Felker</surname><given-names>GM</given-names></name>
<name><surname>Lee</surname><given-names>KL</given-names></name>
<name><surname>Bull</surname><given-names>DA</given-names></name>
<name><surname>Redfield</surname><given-names>MM</given-names></name>
<name><surname>Stevenson</surname><given-names>LW</given-names></name>
<name><surname>Goldsmith</surname><given-names>SR</given-names></name>
<etal/>
</person-group>
<article-title>Diuretic Strategies in Patients with Acute Decompensated Heart Failure</article-title>
<source>N Engl J Med</source>
<year>2011</year>
<volume>364</volume>
<issue>9</issue>
<fpage>797</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1005419</pub-id>
</element-citation>
<mixed-citation>Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. N Engl J Med. 2011;364(9):797-805. doi: 10.1056/NEJMoa1005419.</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Harjola</surname><given-names>VP</given-names></name>
<name><surname>Parissis</surname><given-names>J</given-names></name>
<name><surname>Brunner-La Rocca</surname><given-names>HP</given-names></name>
<name><surname>Čelutkienė</surname><given-names>J</given-names></name>
<name><surname>Chioncel</surname><given-names>O</given-names></name>
<name><surname>Collins</surname><given-names>SP</given-names></name>
<etal/>
</person-group>
<article-title>Comprehensive In-hospital Monitoring in Acute Heart Failure: Applications for Clinical Practice and Future Directions for Research</article-title>
<source>A Statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail</source>
<year>2018</year>
<volume>20</volume>
<issue>7</issue>
<fpage>1081</fpage>
<lpage>1099</lpage>
<pub-id pub-id-type="doi">10.1002/ejhf.1204</pub-id>
</element-citation>
<mixed-citation>Harjola VP, Parissis J, Brunner-La Rocca HP, Čelutkienė J, Chioncel O, Collins SP, et al. Comprehensive In-hospital Monitoring in Acute Heart Failure: Applications for Clinical Practice and Future Directions for Research. A Statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2018;20(7):1081-99. doi: 10.1002/ejhf.1204.</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Marcondes-Braga</surname><given-names>FG</given-names></name>
<name><surname>Moura</surname><given-names>LAZ</given-names></name>
<name><surname>Issa</surname><given-names>VS</given-names></name>
<name><surname>Vieira</surname><given-names>JL</given-names></name>
<name><surname>Rohde</surname><given-names>LE</given-names></name>
<name><surname>Simões</surname><given-names>MV</given-names></name>
<etal/>
</person-group>
<article-title>Emerging Topics Update of the Brazilian Heart Failure Guideline - 2021</article-title>
<source>Arq Bras Cardiol</source>
<year>2021</year>
<volume>116</volume>
<issue>6</issue>
<fpage>1174</fpage>
<lpage>1212</lpage>
<pub-id pub-id-type="doi">10.36660/abc.20210367</pub-id>
</element-citation>
<mixed-citation>Marcondes-Braga FG, Moura LAZ, Issa VS, Vieira JL, Rohde LE, Simões MV, et al. Emerging Topics Update of the Brazilian Heart Failure Guideline - 2021. Arq Bras Cardiol. 2021;116(6):1174-212. doi: 10.36660/abc.20210367.</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rohde</surname><given-names>LEP</given-names></name>
<name><surname>Montera</surname><given-names>MW</given-names></name>
<name><surname>Bocchi</surname><given-names>EA</given-names></name>
<name><surname>Clausell</surname><given-names>NO</given-names></name>
<name><surname>Albuquerque</surname><given-names>DC</given-names></name>
<name><surname>Rassi</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda</article-title>
<source>Arq Bras Cardiol</source>
<year>2018</year>
<volume>111</volume>
<issue>3</issue>
<fpage>436</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="doi">10.5935/abc.20180190</pub-id>
</element-citation>
<mixed-citation>Rohde LEP, Montera MW, Bocchi EA, Clausell NO, Albuquerque DC, Rassi S, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol. 2018;111(3):436-539. doi: 10.5935/abc.20180190.</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Felker</surname><given-names>GM</given-names></name>
<name><surname>Ellison</surname><given-names>DH</given-names></name>
<name><surname>Mullens</surname><given-names>W</given-names></name>
<name><surname>Cox</surname><given-names>ZL</given-names></name>
<name><surname>Testani</surname><given-names>JM</given-names></name>
</person-group>
<article-title>Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review</article-title>
<source>J Am Coll Cardiol</source>
<year>2020</year>
<volume>75</volume>
<issue>10</issue>
<fpage>1178</fpage>
<lpage>1195</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2019.12.059</pub-id>
</element-citation>
<mixed-citation>Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(10):1178-95. doi: 10.1016/j.jacc.2019.12.059.</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mebazaa</surname><given-names>A</given-names></name>
<name><surname>Motiejunaite</surname><given-names>J</given-names></name>
<name><surname>Gayat</surname><given-names>E</given-names></name>
<name><surname>Crespo-Leiro</surname><given-names>MG</given-names></name>
<name><surname>Lund</surname><given-names>LH</given-names></name>
<name><surname>Maggioni</surname><given-names>AP</given-names></name>
<etal/>
</person-group>
<article-title>Long-term Safety of Intravenous Cardiovascular Agents in Acute Heart Failure: Results from the European Society of Cardiology Heart Failure Long-Term Registry</article-title>
<source>Eur J Heart Fail</source>
<year>2018</year>
<volume>20</volume>
<issue>2</issue>
<fpage>332</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1002/ejhf.991</pub-id>
</element-citation>
<mixed-citation>Mebazaa A, Motiejunaite J, Gayat E, Crespo-Leiro MG, Lund LH, Maggioni AP, et al. Long-term Safety of Intravenous Cardiovascular Agents in Acute Heart Failure: Results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20(2):332-41. doi: 10.1002/ejhf.991.</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jardim</surname><given-names>SI</given-names></name>
<name><surname>Santos</surname><given-names>LR</given-names></name>
<name><surname>Araújo</surname><given-names>I</given-names></name>
<name><surname>Marques</surname><given-names>F</given-names></name>
<name><surname>Branco</surname><given-names>P</given-names></name>
<name><surname>Gaspar</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>A 2018 Overview of Diuretic Resistance in Heart Failure</article-title>
<source>Rev Port Cardiol</source>
<year>2018</year>
<volume>37</volume>
<issue>11</issue>
<fpage>935</fpage>
<lpage>945</lpage>
<pub-id pub-id-type="doi">10.1016/j.repc.2018.03.014</pub-id>
</element-citation>
<mixed-citation>Jardim SI, Santos LR, Araújo I, Marques F, Branco P, Gaspar A, et al. A 2018 Overview of Diuretic Resistance in Heart Failure. Rev Port Cardiol. 2018;37(11):935-45. doi: 10.1016/j.repc.2018.03.014.</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bart</surname><given-names>BA</given-names></name>
<name><surname>Goldsmith</surname><given-names>SR</given-names></name>
<name><surname>Lee</surname><given-names>KL</given-names></name>
<name><surname>Givertz</surname><given-names>MM</given-names></name>
<name><surname>O‘Connor</surname><given-names>CM</given-names></name>
<name><surname>Bull</surname><given-names>DA</given-names></name>
<etal/>
</person-group>
<article-title>Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome</article-title>
<source>N Engl J Med</source>
<year>2012</year>
<volume>367</volume>
<issue>24</issue>
<fpage>2296</fpage>
<lpage>2304</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1210357</pub-id>
</element-citation>
<mixed-citation>Bart BA, Goldsmith SR, Lee KL, Givertz MM, O‘Connor CM, Bull DA, et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. N Engl J Med. 2012;367(24):2296-304. doi: 10.1056/NEJMoa1210357.</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hoorn</surname><given-names>EJ</given-names></name>
<name><surname>Ellison</surname><given-names>DH</given-names></name>
</person-group>
<article-title>Diuretic Resistance</article-title>
<source>Am J Kidney Dis</source>
<year>2017</year>
<volume>69</volume>
<issue>1</issue>
<fpage>136</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1053/j.ajkd.2016.08.027</pub-id>
</element-citation>
<mixed-citation>Hoorn EJ, Ellison DH. Diuretic Resistance. Am J Kidney Dis. 2017;69(1):136-42. doi: 10.1053/j.ajkd.2016.08.027.</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Seguro</surname><given-names>LFBC</given-names></name>
<name><surname>Xavier</surname><given-names>JL</given-names><suffix>Jr</suffix></name>
</person-group>
<article-title>Diuréticos no Tratamento da Insuficiência Cardíaca</article-title>
<source>ABC Heart Fail Cardiomyop</source>
<year>2022</year>
<volume>2</volume>
<issue>1</issue>
<fpage>86</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.36660/abchf.20220018</pub-id>
</element-citation>
<mixed-citation>Seguro LFBC, Xavier JL Jr. Diuréticos no Tratamento da Insuficiência Cardíaca. ABC Heart Fail Cardiomyop 2022;2(1):86-93. doi: 10.36660/abchf.20220018.</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Trullàs</surname><given-names>JC</given-names></name>
<name><surname>Morales-Rull</surname><given-names>JL</given-names></name>
<name><surname>Casado</surname><given-names>J</given-names></name>
<name><surname>Carrera-Izquierdo</surname><given-names>M</given-names></name>
<name><surname>Sánchez-Marteles</surname><given-names>M</given-names></name>
<name><surname>Conde-Martel</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Combining Loop with Thiazide Diuretics for Decompensated Heart Failure: The CLOROTIC Trial</article-title>
<source>Eur Heart J</source>
<year>2023</year>
<volume>44</volume>
<issue>5</issue>
<fpage>411</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehac689</pub-id>
</element-citation>
<mixed-citation>Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A, et al. Combining Loop with Thiazide Diuretics for Decompensated Heart Failure: The CLOROTIC Trial. Eur Heart J. 2023;44(5):411-21. doi: 10.1093/eurheartj/ehac689.</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mullens</surname><given-names>W</given-names></name>
<name><surname>Dauw</surname><given-names>J</given-names></name>
<name><surname>Martens</surname><given-names>P</given-names></name>
<name><surname>Verbrugge</surname><given-names>FH</given-names></name>
<name><surname>Nijst</surname><given-names>P</given-names></name>
<name><surname>Meekers</surname><given-names>E</given-names></name>
<etal/>
</person-group>
<article-title>Acetazolamide in Acute Decompensated Heart Failure with Volume Overload</article-title>
<source>N Engl J Med</source>
<year>2022</year>
<volume>387</volume>
<issue>13</issue>
<fpage>1185</fpage>
<lpage>1195</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa2203094</pub-id>
</element-citation>
<mixed-citation>Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-95. doi: 10.1056/NEJMoa2203094.</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ter Maaten</surname><given-names>JM</given-names></name>
<name><surname>Beldhuis</surname><given-names>IE</given-names></name>
<name><surname>van der Meer</surname><given-names>P</given-names></name>
<name><surname>Krikken</surname><given-names>JA</given-names></name>
<name><surname>Postmus</surname><given-names>D</given-names></name>
<name><surname>Coster</surname><given-names>JE</given-names></name>
<etal/>
</person-group>
<article-title>Natriuresis-guided Diuretic Therapy in Acute Heart Failure: A Pragmatic Randomized Trial</article-title>
<source>Nat Med</source>
<year>2023</year>
<volume>29</volume>
<issue>10</issue>
<fpage>2625</fpage>
<lpage>2632</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-023-02532-z</pub-id>
</element-citation>
<mixed-citation>Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Postmus D, Coster JE, et al. Natriuresis-guided Diuretic Therapy in Acute Heart Failure: A Pragmatic Randomized Trial. Nat Med. 2023;29(10):2625-32. doi: 10.1038/s41591-023-02532-z.</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bocchi</surname><given-names>EA</given-names></name>
<name><surname>Biolo</surname><given-names>A</given-names></name>
<name><surname>Moura</surname><given-names>LZ</given-names></name>
<name><surname>Figueiredo</surname><given-names>JA</given-names><suffix>Neto</suffix></name>
<name><surname>Montenegro</surname><given-names>CEL</given-names></name>
<name><surname>Albuquerque</surname><given-names>DC</given-names></name>
</person-group>
<article-title>Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF</article-title>
<source>Arq Bras Cardiol</source>
<year>2021</year>
<volume>116</volume>
<issue>2</issue>
<fpage>355</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.36660/abc.20210031</pub-id>
</element-citation>
<mixed-citation>Bocchi EA, Biolo A, Moura LZ, Figueiredo Neto JA, Montenegro CEL, Albuquerque DC. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF. Arq Bras Cardiol. 2021;116(2):355-8. doi: 10.36660/abc.20210031.</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cox</surname><given-names>ZL</given-names></name>
<name><surname>Collins</surname><given-names>SP</given-names></name>
<name><surname>Aaron</surname><given-names>M</given-names></name>
<name><surname>Hernandez</surname><given-names>GA</given-names></name>
<name><surname>McRae III</surname><given-names>AT</given-names></name>
<name><surname>Davidson</surname><given-names>BT</given-names></name>
<etal/>
</person-group>
<article-title>Efficacy and Safety of Dapagliflozin in Acute Heart Failure: Rationale and Design of the DICTATE-AHF Trial</article-title>
<source>Am Heart J</source>
<year>2021</year>
<volume>232</volume>
<fpage>116</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1016/j.ahj.2020.10.071</pub-id>
</element-citation>
<mixed-citation>Cox ZL, Collins SP, Aaron M, Hernandez GA, McRae III AT, Davidson BT, et al. Efficacy and Safety of Dapagliflozin in Acute Heart Failure: Rationale and Design of the DICTATE-AHF Trial. Am Heart J. 2021;232:116-24. doi: 10.1016/j.ahj.2020.10.071.</mixed-citation>
</ref>
</ref-list>
</back>
<sub-article article-type="translation" id="S1" xml:lang="pt">
<front-stub>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Ponto de Vista</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Resistência a Diuréticos de Alça: Como Abordar no Cenário Atual?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-9049-1805</contrib-id>
<name><surname>Savaris</surname><given-names>Simone L.</given-names></name>
<role>Redação do manuscrito e Revisão crítica do manuscrito quanto ao conteúdo</role>
<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-2612-8040</contrib-id>
<name><surname>Andrade</surname><given-names>Fernanda Almeida</given-names></name>
<role>Redação do manuscrito e Revisão crítica do manuscrito quanto ao conteúdo</role>
<xref ref-type="aff" rid="aff5"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-0706-0933</contrib-id>
<name><surname>Schwartzmann</surname><given-names>Pedro V.</given-names></name>
<xref ref-type="aff" rid="aff6"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c2"/>
<role>Redação do manuscrito e Revisão crítica do manuscrito quanto ao conteúdo</role>
</contrib>
<aff id="aff4">
<label>1</label>
<addr-line>
<named-content content-type="city">São Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Hospital São Luiz, Rede D’Or, São Paulo, SP – Brasil</institution>
</aff>
<aff id="aff5">
<label>2</label>
<addr-line>
<named-content content-type="city">São Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade Federal de São Paulo / UNIFESP, São Paulo, SP – Brasil</institution>
</aff>
<aff id="aff6">
<label>3</label>
<addr-line>
<named-content content-type="city">Ribeirão Preto</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Hospital da Unimed, Ribeirão Preto-SP e Centro Avançado de Pesquisa – CAPED, Ribeirão Preto, SP – Brasil</institution>
</aff>
</contrib-group>
<author-notes>
<corresp id="c2"><bold>Correspondência: Pedro V. Schwartzmann •</bold> Centro de Pesquisa - CAPED - Av. Cel. Fernando Ferreira Leite, 1540. CEP <postal-code>14026-900</postal-code>, Centro Médico Ribeirão Shopping, Jardim California, Ribeirão Preto, SP - Brasil E-mail: <email>pedrovs.usp@gmail.com</email></corresp>
<fn fn-type="conflict"><p><bold>Potencial conflito de interesse</bold></p>
<p>Não há conflito com o presente artigo</p></fn>
</author-notes>
<kwd-group xml:lang="pt">
<title>Palavras-chave</title>
<kwd>Diuréticos</kwd>
<kwd>Resistência</kwd>
<kwd>Refratariedade</kwd>
</kwd-group>
</front-stub>
<body>
<p>Congestão persistente a despeito do uso de diurético de alça é um dos desafios mais importantes no manejo de insuficiência cardíaca (IC) aguda e está associada a pior prognóstico. Um dos principais motivos para essa persistência na congestão é a resistência aos diuréticos de alça (RD), que pode ser definida como uma redução de sensibilidade aos diuréticos, com redução de natriurese e diurese e limitação de alcance da euvolemia – a RD pode atingir até 1/3 dos pacientes admitidos por IC aguda e aumenta independentemente o risco de morte em 1,37 vezes.<sup><xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref></sup></p>
<p>Em relação aos mecanismos de RD, há diversos fatores possivelmente implicados, como biodisponibilidade do diurético e entrega no seu sítio de ação, ativação neuro-hormonal, adaptação tubular compensatória e interação com outras drogas (<xref ref-type="table" rid="t2">Tabela 1</xref>). Vale ressaltar que, em pacientes com congestão sistêmica importante, é possível que a ocorrência de edema de alças intestinais, prejudicando a absorção dos diuréticos, possa ser um dos fatores associados a menor ação da furosemida via oral.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Além disso, a presença de doença renal crônica associada ao quadro de IC leva a uma menor taxa de filtração glomerular e consequente menor efeito dos diuréticos no néfron. A hipoalbuminemia também se associa a maior resistência aos RD, haja vista a maior afinidade dos diuréticos às moléculas ligadas à albumina e um menor efeito do diurético no seu sítio de ação, que é o néfron.<sup><xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref></sup></p>
<table-wrap id="t2">
<label>Tabela 1</label>
<caption><title>Mecanismos de resistência aos diuréticos de alça<sup><xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref></sup></title></caption>
<table frame="hsides" rules="groups">
<colgroup width="50%">
<col/>
<col/>
</colgroup>
<tbody style="border-bottom: thin solid; border-color: #000000">
<tr style="background-color:#E8CCBF">
<td align="center" valign="top">Biodisponibilidade do diurético e menor efeito no néfron</td>
<td align="center" valign="top">Má-aderência aos diuréticos <break/>Doses muito baixas <break/>Má-absorção (ex: edema de alças intestinais) <break/>Hipoalbuminemia <break/>Síndrome nefrótica <break/>Cirrose hepática <break/>Má-perfusão renal</td>
</tr>
<tr>
<td align="center" valign="top">Ativação neuro-hormonal</td>
<td align="center" valign="top">Ativação do SRAA <break/>Ativação sistema nervoso simpático</td>
</tr>
<tr style="background-color:#E8CCBF">
<td align="center" valign="top">Adaptação tubular compensatória</td>
<td align="center" valign="top">Retenção de sódio compensatória após o efeito do diurético <break/>Hipertrofia e hiperplasia das células do túbulo distal <break/>Aumento da absorção de sódio no túbulo proximal e distal</td>
</tr>
<tr>
<td align="center" valign="top">Interação com outras drogas</td>
<td align="center" valign="top">Ex: AINEs</td>
</tr>
<tr style="background-color:#E8CCBF">
<td align="center" valign="top">Diagnóstico incorreto</td>
<td align="center" valign="top">Edema linfático <break/>Depleção de volume intravascular e edema de terceiro espaço</td>
</tr>
<tr>
<td align="center" valign="top">Má-aderência as recomendações de restrição de sódio e água</td>
<td align="center" valign="top" />
</tr>
<tr style="background-color:#E8CCBF">
<td align="center" valign="top">Insuficiência renal crônica</td>
<td align="center" valign="top" />
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN2"><p>SRAA: sistema renina-angiotensina-aldosterona; AINEs: anti-inflamatórios não-esteroidais.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>A resistência aos diuréticos também pode ocorrer devido à maior absorção de sódio e cloro no túbulo proximal, interferindo no sistema do co-transportador de sódio-potássio-cloro no néfron distal e minimizando o efeito do diurético de alça. A readaptação tubular compensatória é outro mecanismo que explica a menor resposta ao diurético e ocorre quando há um aumento na reabsorção de sódio no túbulo proximal. Ao mesmo tempo, o uso crônico dos RD - que inibem a captação de sódio na alça de Henle – leva ao aumento da quantidade de sódio no túbulo distal com hiperplasia e hipertrofia compensatórias.<sup><xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref></sup></p>
<p>A ativação neuro-hormonal está diretamente ligada ao sistema renina-angiotensina-aldosterona e os RD podem ativar esse sistema através de uma variedade de mecanismos, levando a maior reabsorção de sódio e a retenção de sódio pós uso de diurético, bem como a queda do volume urinário após várias doses de diurético. Por fim, a interação com outros medicamentos também pode prejudicar o efeito do diurético de alça, como por exemplo o uso de anti-inflamatórios não-esteroidais.<sup><xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref></sup></p>
<p>Para vencer a resistência diurética é fundamental compreender os mecanismos de resistência e buscar a causa, que pode ser distinta a depender das particularidades de cada paciente. Aumentar a dose do diurético, optar por infusão contínua, fazer o bloqueio sequencial do néfron ou, ainda, utilizar solução salina hipertônica (SSH) são algumas opções para manejar os casos em que se é identificada resistência ao diurético de alça.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
<p>Nos estudos CLOROTIC e ADVOR, a associação de diuréticos de outras classes em conjunto com o diurético de alça, em pacientes com IC aguda se associou a melhor resposta diurética.<sup><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup></p>
<p>O estudo CLOROTIC incluiu pacientes com IC descompensada e congestão persistente, e a associação da hidroclorotiazida via oral com furosemida endovenosa resultou em maior perda de peso, maior débito urinário e descongestão, porém houve piora de função renal com mais frequência nos pacientes que receberam diurético tiazídico, sem diferença em mortalidade ou risco de hiponatremia ou hipocalemia.<sup><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup></p>
<p>Já o estudo ADVOR avaliou se a associação da acetazolamida, inibidor da anidrase carbônica que reduz a absorção de sódio no túbulo proximal, poderia melhorar a resposta aos RD e levar a maior e mais rápida descongestão nos pacientes com IC aguda e sobrecarga de volume. Nesse estudo, o uso do diurético de alça com o inibidor da anidrase carbônica resultou em maior débito urinário e natriurese, achados consistentes com maior eficácia diurética, sem diferença significativa em piora da função renal, hipocalemia ou hipotensão.<sup><xref ref-type="bibr" rid="B13">13</xref></sup></p>
<p>Outrossim, a quantificação do sódio urinário também pode contribuir na avaliação da resposta ao diurético, como demonstrado no estudo ADVOR e no estudo PUSH-AHF. Neste, os investigadores avaliaram a efetividade da terapia diurética guiada pela natriurese e a quantificação precoce e repetida do sódio urinário associada aos ajustes subsequentes do tratamento diurético levaram a uma melhor resposta diurética nas primeiras 48h de tratamento, sem impacto em mortalidade ou re-hospitalização.<sup><xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref></sup></p>
<p>Uma outra alternativa é o uso de SSH associada a furosemida endovenosa em altas doses. Apesar de pouca evidência para sua utilização, o racional para o seu uso é o efeito osmótico, mobilizando o líquido extravascular e corrigindo a hiponatremia e a hipocloremia que, como descrito nos mecanismos de resistência anteriormente, podem estar ligadas à resistência a diurético.<sup><xref ref-type="bibr" rid="B14">14</xref></sup></p>
<p>Ademais, os inibidores da SGLT2, apesar de não serem uma classe de diuréticos propriamente dita, dentre outros mecanismos de ação, inibem a reabsorção de glicose no túbulo contorcido proximal resultando em glicosúria. Como mostrado no estudo DICTATE-AHF, essa classe de medicações pode também contribuir para a eficácia diurética aumentando a natriurese e a diurese para a mesma dose de diurético de alça, reduzindo a dose total e duração do uso de RD, bem como o tempo de hospitalização em pacientes com IC agudamente descompensados.<sup><xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref></sup></p>
<p>Nos casos de congestão refratária, pode-se lançar mão do manejo com infusão contínua de furosemida na dose de 40 a 150 mg/hora associada ao bloqueio sequencial do néfron com associação de espironolactona e hidroclorotiazida. Nos casos de anasarca ou ascite refratária e hiponatremia severa deve-se realizar paracentese para redução da pressão intra-abdominal; sugere-se ainda a solução hipertônica de cloreto de sódio para aumentar a taxa de enchimento plasmático mobilizando líquido do meio extracelular para o intracelular. Quando houver indicação de terapia substitutiva renal associa-se a esta a ultrafiltração; contudo vale ressaltar que a utilização da ultrafiltração não se mostrou superior aos diuréticos na descongestão e evolução dos pacientes descompensados, além de ter maior potencial de complicações.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup></p>
<p>Uma sugestão de fluxograma contemplando essas novas evidências recentes encontra-se na <xref ref-type="fig" rid="f2">Figura 1</xref>.</p>
<fig id="f2">
<label>Figura 1</label>
<caption><title>Manejo de diureticoterapia na insuficiência cardíaca aguda.</title></caption>
<graphic xlink:href="2764-3107-abchf-003-02-e20230090-gf01-pt.tif"/>
</fig>
<sec sec-type="conclusions">
<title>Conclusão</title>
<p>A resistência aos diuréticos é uma realidade frequente em muitos pacientes com IC e está associada a pior prognóstico. Diversos estudos recentes endereçaram esse problema para buscar alternativas de tratamento da RD, seja com monitoramento mais frequente ou usando natriurese para auxiliar o momento de associar diuréticos. Sempre importante buscar o tratamento da congestão com doses adequadas de diurético de alça, associação com os inibidores de SGLT2 e, em casos refratários, considerar associação de outras classes de diurético como acetazolamida ou tiazídicos.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn4"><p><bold>Fontes de financiamento</bold></p>
<p>O presente estudo não teve fontes de financiamento externas.</p></fn>
<fn fn-type="other" id="fn5"><p><bold>Vinculação acadêmica</bold></p>
<p>Não há vinculação deste estudo a programas de pós-graduação.</p></fn>
<fn fn-type="other" id="fn6"><p><bold>Aprovação ética e consentimento informado</bold></p>
<p>Este artigo não contém estudos com humanos ou animais realizados por nenhum dos autores.</p></fn>
</fn-group>
</back>
</sub-article>
</article>